BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 8632328)

  • 1. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
    Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
    J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist-dependent inhibition by peptide and nonpeptide endothelin receptor antagonists in the rabbit isolated pulmonary artery.
    Beck GR; Douglas SA; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S385-8. PubMed ID: 8587422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
    Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670.
    Ohlstein EH; Beck GR; Douglas SA; Nambi P; Lago MA; Gleason JG; Ruffolo RR; Feuerstein G; Elliott JD
    J Pharmacol Exp Ther; 1994 Nov; 271(2):762-8. PubMed ID: 7965794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
    Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
    J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
    Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of two novel mixed ETA/ETB receptor antagonists, BQ-928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit.
    Maurice MC; Gratton JP; D'Orléans-Juste P
    Br J Pharmacol; 1997 Jan; 120(2):319-25. PubMed ID: 9117126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist.
    Reynolds EE; Keiser JA; Haleen SJ; Walker DM; Olszewski B; Schroeder RL; Taylor DG; Hwang O; Welch KM; Flynn MA
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1410-7. PubMed ID: 7791115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
    Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic evidence for the presence of three functional endothelin receptor subtypes in rabbit saphenous vein.
    Douglas SA; Beck GR; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S163-8. PubMed ID: 8587352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.
    Balwierczak JL; Bruseo CW; DelGrande D; Jeng AY; Savage P; Shetty SS
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S393-6. PubMed ID: 8587424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
    Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
    J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
    Willette RN; Sauermelch CF; Storer BL; Guiney S; Luengo JI; Xiang JN; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S149-57. PubMed ID: 9595425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?
    Hay DW; Luttmann MA; Pullen MA; Nambi P
    J Pharmacol Exp Ther; 1998 Feb; 284(2):669-77. PubMed ID: 9454813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein.
    Douglas SA; Beck GR; Elliott JD; Ohlstein EH
    Br J Pharmacol; 1995 Apr; 114(8):1529-40. PubMed ID: 7599920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the contractile effects and binding kinetics of endothelin-1 and sarafotoxin S6b in rat isolated renal artery.
    Devadason PS; Henry PJ
    Br J Pharmacol; 1997 May; 121(2):253-63. PubMed ID: 9154335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.